Cardiff Oncology (CRDF)

• Market cap: $110M
• 1 day: -1.23%
• 5 days: 1.9%
• 1 month: -42.7%
• 3 months: -17.86%
• 6 months: -29.39%
• Year to date: -39.47%
• 1 year: -65.74%
• 5 years: -85.75%
• 10 years: -99.51%
• Sector: Healthcare
• Industry: Biotechnology

About: Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Employees: 33